Report #2850448

Received Jul 21, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: FL
Recovered: Unknown
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
TDAP	TDAP (BOOSTRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	—	—

Symptoms (1)

Extra dose administered

Symptom narrative

A patient received a tetanus vaccine (Boostrix) 5 months apart; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 80-year-old female patient who received DTPa (Reduced antigen) (Boostrix) for prophylaxis. Previously administered products included Boostrix (received 1st dose on an unknown date). On an unknown date, the patient received the 2nd dose of Boostrix. On an unknown date, an unknown time after receiving Boostrix, the patient experienced extra dose administered (Verbatim: A patient received a tetanus vaccine (Boostrix) 5 months apart). The outcome of the extra dose administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 10-JUL-2025 On 10th July 2025 a pharmacist called to ask for a patient who received a tetanus vaccine (Boostrix) 5 months apart which led to extra dose administration, and wanted to know if was there anything that they need to do?